

## Anaesthesia recommendations for patients suffering from **Hunter syndrome**

**Disease name:** Hunter syndrome

**ICD 10:** E 76.1

**Synonyms:** Mucopolysaccharidosis, Type II; MPS2; Iduronate-2-sulfatase deficiency; IDS deficiency; sulfo-iduronate sulfatase deficiency; SIDS deficiency

**Disease summary:** Hunter syndrome is an X-linked recessive disease caused by deficiency of the lysosomal enzyme iduronate-2-sulfatase, leading to progressive accumulation of glycosaminoglycans in nearly all cell types, tissues, and organs. The estimated prevalence is 1 in 70 000 – 80 000 male live births in Europe. The disease affects males almost exclusively, although female patients have been identified. Clinical manifestations include: facial dysmorphism; hepatosplenomegaly; progressive airway obstruction; cardiac disease; hearing loss; loss of vision and musculoskeletal deformities. Severely affected patients also suffer from progressive cognitive dysfunction and behavioural disturbances, and have a life expectancy of less than 2 decades. The most common cause of death is airway impairment.

Enzyme replacement therapy by idursulfase may improve certain symptoms. Unfortunately, intravenously administered idursulfase does not cross the blood-brain barrier and will not alleviate neurological symptoms. It is unclear whether the potential benefits of successful stem cell transplantation outweigh the risks of this procedure.

---

Medicine in progress



Perhaps new knowledge

Every patient is unique

Perhaps the diagnostic is wrong

---



Find more information on the disease, its centres of reference and patient organisations on Orphanet: [www.orpha.net](http://www.orpha.net)

---

## **Typical surgery**

---

Prevalence in descending order: tympanostomy, hernia repair, (adeno-) tonsillectomy, carpal tunnel release, dental procedures, intracranial shunt insertion / revision, trigger-finger release, spine decompression, feeding tube insertion, valve replacement / repair, spine fusion. Combining minor surgical procedures and various diagnostic procedures requiring anaesthesia may be appropriate.

## **Type of anaesthesia**

---

General anaesthesia should be undertaken with great care. General anaesthesia is a difficult and potentially high-risk procedure in MPS2 patients, due to the airway management difficulties. Anaesthesia becomes progressively more difficult with age. Consider local or regional anaesthesia where possible.

## **Necessary additional diagnostic procedures (preoperative)**

---

Review by (paediatric) ENT specialist for each new diagnosis, including examination of upper airway and sleep study. Airway manifestations may include: adenotonsillar hypertrophy, macroglossia, upper airway obstruction, obstructive sleep apnoea (OSA), narrowing of the tracheal lumen and tracheobronchomalacia.

Review by (paediatric) cardiologist for each new diagnosis, including physical examination, electrocardiogram, chest X-ray and echocardiogram. Holter monitoring, if arrhythmia or irregular heartbeat is suspected. Cardiac involvement may consist of valvular abnormalities, left ventricular hypertrophy, hypertension.

Spirometer, if the patient is fully cooperative and when there is a history of frequent respiratory infections and/or kyphoscoliosis or as means to evaluate pulmonary involvement. Obstructive lung disease is caused by glycosaminoglycan deposits in soft tissue of upper and lower respiratory tract; restrictive lung disease is caused by kyphoscoliosis and altered chest wall dynamics. Standard reference values may not apply to MPS2 patients due to skeletal dysplasia and extremely short stature; intra individual change obtained by an experienced physician who knows the patient, is mostly the best way to judge the diagnostic findings in this progressive disease.

Neurological examination (assessment of hyperreflexia), a flexion/extension X-ray of the spine can be recommended before the procedure to assess the risk of spinal cord compression.

Review by (paediatric) anaesthesiologist for each new diagnosis, after receiving full report of previous investigations and course of previous anaesthetics. The emphasis should lie on the evaluation of the airway. Short neck, immobile jaw, glycosaminoglycan deposits throughout the airway can make ventilation and / or intubation extremely difficult.

A multidisciplinary meeting is warranted, to assess the risk benefit ratio of any planned procedure.

The anaesthetic plan and the potential risks of a procedure should be discussed with the patient / parents; discuss the possibility of abandoning the procedure due to anaesthetic difficulty.

---

### **Particular preparation for airway management**

---

Basic preparation for difficult airway management includes: informing the patient / parents; availability of equipment and experienced personnel for management of a difficult airway; assigning an individual to provide assistance when a difficult airway is encountered; pre-anaesthetic pre-oxygenation by facemask and administration of supplemental oxygen throughout the process of difficult airway management.

Plan and discuss the strategy with the experienced team including the consideration of various interventions designed to facilitate ventilation / intubation should a difficult airway occur; make a plan and a backup plan. Maintenance of spontaneous respiration is recommended to avoid the 'cannot intubate cannot ventilate' scenario.

Awake fiberoptic intubation should be considered, but may not be feasible due to patient age and /or impaired neurodevelopment.

Retaining an unobstructed airway by facemask ventilation can be difficult, an oro- or nasopharyngeal airway, applying chin lift of jaw thrust or increasing positive pressure may be helpful. Patients with potentially unstable necks require induction of anaesthesia with minimal or no neck movement using manual in-line stabilisation in order to prevent spinal cord damage.

Supraglottic Airway devices such as Laryngeal Mask Airway and I-gel have been used successfully and may serve as a conduit for fiberoptic intubation.

Video-assisted laryngoscopy has been used successfully.

Tracheotomy, to safeguard an anticipated difficult airway prior to a planned surgical procedure, or to treat progressive upper airway obstruction, has been used successfully. An emergency tracheostomy is an extremely difficult procedure in these patients and may not be feasible if the airway cannot be managed.

Endotracheal extubation should only be undertaken after full reversal of the neuromuscular blockade and if the patient is fully awake, coughing efficiently and breathing adequately. Consider intraoperative steroids (dexamethasone) to help reduce postoperative oral mucosal and tongue swelling. Extubation should be performed in an area where all the necessary personnel and equipment for (re-) intubation is available immediately.

---

### **Particular preparation for transfusion or administration of blood products**

---

Stem cell transplantation candidates require special blood components, such as leukocyte-reduced cellular, cytomegalovirus seronegative, and/or gamma-irradiated components. Transplantation patients may require a large number of transfused blood products, as a result of pancytopenia and organ and tissue damage sustained during the procedure. After successful stem cell transplantation, blood type changes to the blood type of the donor.

### **Particular preparation for anticoagulation**

---

No reports.

### **Particular precautions for positioning, transport or mobilisation**

---

Restricted joint range motion in elbow, shoulder, hip, knee and ankle. Extension is the most severely affected movement, with exception of the shoulder. Instability of the atlanto-axial joint and spinal cord compression at the cervicocranial and thoracolumbar region due to spinal canal narrowing has been reported. Consider awake positioning prior to anaesthesia to find out appropriate position and adequate materials.

### **Probable interaction between anaesthetic agents and patient's long-term medication**

---

No reports on interaction between anaesthetic agents and idursulfase.

### **Anaesthesiologic procedure**

---

Patients with MPS2 should only undergo anaesthesia / surgery in centres experienced with the perioperative management of individuals with this disease.

General anaesthesia should be undertaken with great care; consider local or (ultrasound guided) regional anaesthesia where possible.

Carefully planning of the procedure; make sure personnel experienced with the perioperative management of MPS2 patients are available, including an experienced ENT surgeon. Combining minor surgical procedures and various diagnostic procedures requiring anaesthesia may be appropriate.

Provide anaesthesia in MPS2 patients in a fully equipped operating room, with a difficult airway trolley at hand. Consider induction of anaesthesia in the operating room before transporting the MPS2 patient to the MRI / CT scan suite. Intensive care back up.

Induction of general anaesthesia should be executed in such manner that spontaneous respiration is maintained; for example with mask induction, propofol infusion or ketamine.

Anaesthesia for short procedures can be performed either using a facemask with spontaneous breathing technique or by LMA (laryngeal mask airway).

Patients with MPS2 may be sensitivity to opioids and may require a lower dose of opioids, particularly if OSA is present.

Neuromuscular blocking agents can be used safely in these patients, but are best omitted until the endotracheal intubation has been achieved and the airway is secured.

### **Particular or additional monitoring**

---

Monitoring of the neuromuscular blockade is recommended if any neuromuscular blocking agent is used.

Neurophysiological using somatosensory or motor evoked potentials (SSEPs or MEPs) if spinal cord is compromised by position or surgical procedure.

### **Possible complications**

---

Inability to ventilate or intubate the patient.

Complete airway obstruction, resulting in hypoxemia and cardiac arrest.

Post-obstructive (negative pressure) pulmonary oedema

Failure to maintain airway after extubation, stridor, upper or lower airway collapse

Need for urgent reintubation or tracheostomy

Delayed awakening and / or return of spontaneous ventilation due to an increased sensitivity to opioids.

Upper spinal cord injury.

### **Postoperative care**

---

Degree of postoperative monitoring is depending on surgical procedure and preoperative condition of the patient. Intensive care is not mandatory, but intensive care facilities should be one site.

Continued monitoring of the airway to detect airway obstruction episodes and desaturation.

In case of (postoperative) respiratory failure consider applying CPAP (Continuous Positive Airway Pressure).

### **Information about emergency-like situations / Differential diagnostics**

---

*Caused by the illness to give a tool to distinguish between a side effect of the anaesthetic procedure and a manifestation of the diseases, e.g.:*

Acute airway compromise and respiratory failure can be caused by the illness and as a side effect of the anaesthetic procedure.

### **Ambulatory anaesthesia**

---

Ambulatory anaesthesia *if at all* should only be done in MPS2 patients with no- obstructive airway or cardiovascular disease and low risk surgery.

### **Obstetrical anaesthesia**

---

There is one report of a woman with the attenuated form of MPS2, short stature, coarse facial features, mild retardation, no hepatosplenomegaly, no enlarged tongue, unremarkable echocardiography, who completed a pregnancy successfully and gave birth to a female baby carrying the same mutation. There are no reports on obstetrical anaesthesia.

## Literature and Internet links

1. Scarpa M, Almássy Z, Beck M, et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. *Orphan Journal of Rare Diseases* 2011; 6: 72
2. Wraith JE, Beck M, Giugliani R, et al. Initial report from the Hunter Outcome Survey. *Genetics in Medicine* 2008; 10(7): 508 - 816
3. The Hunter disease eClinic at <http://www.lysosomalstorageresearch.ca>
4. Jones SA, Almássy Z, Beck M, et al. Mortality and cause of death in mucopolysaccharidosis type II – a historical review based on data from the Hunter Outcome Survey (HOS). *J Inherit Metab Dis* 2009; 32:534-543
5. Leighton SEJ, Papsin B, Vellodi A et al. Disordered breathing during sleep in patients with mucopolysaccharidoses. *Int J Ped Otorhinolaryng* 2001; 58: 127-138
6. Wooten WI, Muenzer J, Vaughn BV, Muhlebach MS. Relationship of sleep to pulmonary function in mucopolysaccharidosis II. *J Pediatr* 2013; 162(6): 1210-1215
7. Kampmann C, Beck M, Morin I, Loehr JP. Prevalence and characterization of cardiac involvement in Hunter syndrome. *J Pediatr* 2011; 159: 327-331
8. Sohn YB, Choi EW, Kim SJ et al. Retrospective analysis of the clinical manifestations and survival of Korean patients with mucopolysaccharidosis type II: emphasis on the cardiovascular complication and mortality cases. *Am J Med Genet* 2010; 158A: 90-96
9. Holt JB, Poe MD, Escolar ML. Natural progression of neurological disease in mucopolysaccharidosis type II. *Pediatrics* 2011; 127; e1258
10. Link B, Lapagesse de Camargo Pinto L, Giugliani R et al. Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey. *Orthopedic Reviews* 2010; 2 (e16): 56-64
11. Sohn YB, Kim SJ, Park SW et al. A mother and daughter with the p.R443X mutation of mucopolysaccharidosis type II: genotype and phenotype analysis. *Am J Med Genet* 2010; 152A: 3129-3132
12. Mendelsohn NJ, Harmatz P, Bodamer O et al. Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): data from the Hunter Outcome Survey. *Genetics in Medicine* 2010; 12(12): 816-822
13. Walker R, Belani G, Braunlin EZ et al. Anaesthesia and airway management in mucopolysaccharidosis. *J Inherit Metab Dis* 2013; 36: 211-219
14. Frawley G, Fuenzalida D, Donath S et al. A retrospective audit of anaesthetic techniques and complications in children with mucopolysaccharidoses. *Ped An* 2012; 22: 737-744
15. Megens JHAM, Wit M de, Hasselt PM van. Perioperative complications in patients diagnosed with mucopolysaccharidosis and the impact of enzyme replacement therapy followed by hematopoietic stem cell transplantation at early age. *Ped An* 2014, 24: 521-527
16. Practice guidelines for management of the difficult airway: An Updated Report by the American Society of Anesthesiologists Task Force on Management of the Difficult Airway. *Anesthesiology* 2013; 118: 251–70
17. Walker RWM, Allen DL, Rothera MR. A fiberoptic intubation technique for children with mucopolysaccharidoses using the laryngeal mask airway. *Ped An* 1997; 7; 421-426
18. Michalek P, Hodgkinson PH, Donaldson W. Fiberoptic intubation through an I-gel supraglottic airway in two patients with predicted difficult airway and intellectual disability. *Anesth Analg* 2008; 106; 1501-1504
19. Malik V, Nichani J, Rothera MP et al. Tracheostomy in mucopolysaccharidosis type II (Hunter's syndrome). *Int J Ped Otorhinolaryng* 2013; 77; 1204-1208
20. Walker RWM, Colovic V, Robinson DN and Dearlove OR. Postobstructive pulmonary oedema during anaesthesia in children with mucopolysaccharidoses. *Ped An* 2003; 13; 441-447
21. Kreidstein A, Boorin MR, Crespi P et al. Delayed awakening from general anaesthesia in a patient with Hunter syndrome. *Can J Anaesth* 1994; 41(5): 423-426
22. Gajewski JL, Johnson VV, Sandler SG et al. A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation. *Blood* 2008; 112: 3036-3047.

---

**Last date of modification: September 2014**

---

*This guideline has been prepared by:*

**Author**

**Johanna Megens**, Anaesthesiologist, Wilhelmina Kinderziekenhuis, Universitair Medisch Centrum Utrecht, The Netherlands

[J.H.A.M.Megens@umcutrecht.nl](mailto:J.H.A.M.Megens@umcutrecht.nl)

**Peer revision 1**

**Robert Walker**, Anaesthesiologist, Royal Manchester Children's Hospital, Manchester, UK

[Robert.Walker@cmft.nhs.uk](mailto:Robert.Walker@cmft.nhs.uk)

**Matthias Schäfer**, Anaesthesiologist, Stiftungsklinikum Mittelrhein, Koblenz, Germany

[matthias.schaefer@stiftungsklinikum.de](mailto:matthias.schaefer@stiftungsklinikum.de)

**Peer revision 2**

**Michael Beck**, Institute for Human Genetics, University Hospital Mainz, Germany

[Michael.Beck@unimedizin-mainz.de](mailto:Michael.Beck@unimedizin-mainz.de)

---